房颤卒中预防中的共享决策:随机对照试验研究方案
本研究方案描述一项多中心、就诊层面的随机对照试验,旨在评估在临床就诊中使用ANTICOAGULATION CHOICE对话工具相比常规护理,对非瓣膜性房颤卒中风险患者的共享决策质量、抗凝治疗选择与依从性的影响。计划纳入999例患者及其临床医生,主要结局为参与者感知的共享决策质量。
要点
- 多中心随机试验评估ANTICOAGULATION CHOICE对话工具对房颤共享决策质量的影响。
- 纳入标准为非瓣膜性房颤且有卒中风险(男性CHA2DS2-VASc≥1,女性≥2)。
- 主要结局为就诊后调查评估的共享决策质量,包括知识传递、决策一致性、沟通质量和满意度。
核心结论
- 本研究将提供ANTICOAGULATION CHOICE对话工具对共享决策质量和过程、治疗选择及治疗依从性影响的有效且精确的测量。
研究设计与样本
- 多中心、就诊层面、随机对照试验,比较使用ANTICOAGULATION CHOICE对话工具与常规护理。
- 参与中心包括美国明尼苏达州的一个学术医院系统、一个郊区社区团体实践和一个城市安全网医院。
- 计划纳入999例患者及其临床医生。
关键数值与推荐
- 纳入标准:非瓣膜性房颤且有卒中风险,男性CHA2DS2-VASc评分≥1,女性≥2。
- 主要结局:参与者感知的共享决策质量,通过就诊后调查评估知识传递、决策一致性、沟通质量和决策过程满意度。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nonvalvular atrial fibrillation (AF) is a common ongoing health problem that places patients at risk of stroke. Whether and how a patient addresses this risk depends on each patient's goals, context, and values. Consequently, leading cardiovascular societies recommend using shared decision making (SDM) to individualize antithrombotic treatment in patients with AF. The aim of this study is to assess the extent to which the ANTICOAGULATION CHOICE conversation tool promotes high-quality SDM and influences anticoagulation uptake and adherence in patients with AF at risk of strokes. METHODS: This study protocol describes a multicenter, encounter-level, randomized trial to assess the effect of using the ANTICOAGULATION CHOICE conversation tool in the clinical encounter, compared to usual care. The participating centers include an academic hospital system, a suburban community group practice, and an urban safety net hospital, all in Minnesota, USA. Patients with ongoing nonvalvular AF at risk of strokes (CHA2DS2-VASc score ≥ 1 in men, or ≥ 2 in women) will be eligible for participation. We aim to include 999 patients and their clinicians. The primary outcome is the quality of SDM as perceived by participants, and as assessed by a post-encounter survey that ascertains (a) knowledge transfer, (b) concordance of the decision made, (c) quality of communication, and (d) satisfaction with the decision-making process. Recordings of encounters will be reviewed to assess the extent of patient involvement and how participants use the tool (fidelity). Anticoagulant use, choice of agent, and adherence will be drawn from patients' medical and pharmacy records. Strokes and bleeding events will be drawn from patient records. DISCUSSION: This study will provide a valid and precise measure of the effect of the ANTICOAGULATION CHOICE conversation tool on SDM quality and processes, and on the treatment choices and adherence to therapy among AF patients at risk of stroke. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02905032 . Registered on 9 September 2016.
引用
- Kunneman M, Branda ME, Noseworthy PA, et al. Shared decision making for stroke prevention in atrial fibrillation: study protocol for a randomized controlled trial. Trials. 2017. PMID: 28962662. doi:10.1186/s13063-017-2178-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。